×

Avalanche Biotechnologies to Present at the 26th Annual Piper Jaffray Healthcare Conference

MENLO PARK, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 1:30 pm EST in New York, NY.

About Avalanche Biotechnologies, Inc.

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit www.avalanchebiotech.com.

CONTACT: Investor Contact: Chris Erdman MacDougall Biomedical Communications (781) 235-3060 cerdman@macbiocom.com Media Contact: Kathy Vincent (310) 403-8951 kathy@kathyvincent.com

Source:Avalanche Biotechnologies, Inc.